Literature DB >> 20573058

Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.

Hye Kyeong Park1, Kyeongman Jeon, Won-Jung Koh, Gee Young Suh, Hojoong Kim, O Jung Kwon, Man Pyo Chung, Kyung Soo Lee, Young Mog Shim, Joungho Han, Sang-Won Um.   

Abstract

BACKGROUND AND
OBJECTIVE: The introduction of ¹⁸F-FDG PET/CT has enhanced the diagnostic accuracy of nodal staging for non-small cell lung cancer (NSCLC). We analysed risk factors for occult nodal metastasis in patients with clinical stage IA NSCLC as determined by ¹⁸F-FDG PET/CT.
METHODS: Data for 147 patients diagnosed as clinical stage IA NSCLC by PET/CT from 2005 to 2007 were retrospectively reviewed. All study patients underwent ¹⁸F-FDG PET/CT for lung cancer staging. They also underwent cervical mediastinoscopy or systematic lymph node dissection.
RESULTS: Cervical mediastinoscopy was performed in 78 patients (53.1%), and N2 involvement was detected in 3.8% (3/78) of these patients. Thoracotomy with systematic lymph node dissection was done in 144 patients. Four patients (2.8%, 4/144) were diagnosed with N2 disease after systematic lymph node dissection. Total N2 involvement was 4.8% (7/147). As 9.5% (14/147) of study patients had N1 disease, 14.3% (21/147) of patients had occult nodal (N1 or N2) metastasis. In univariate analyses, larger tumour size and a higher primary tumour maximum standardized uptake value >7.3 (SUV(max)) were associated with occult nodal metastasis. Multivariate analysis demonstrated that a primary tumour SUV(max) >7.3 was an independent predictor of occult nodal metastasis (odds ratio: 7.574; P = 0.001).
CONCLUSIONS: Preoperative PET/CT scans contribute to reduce the frequency of occult nodal metastasis compared with those reported in the pre-PET/CT era. The higher SUV(max) in primary tumour was an independent predictor of occult nodal metastasis in patients with clinical stage IA NSCLC by PET/CT.
© 2010 The Authors. Journal compilation © 2010 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573058     DOI: 10.1111/j.1440-1843.2010.01793.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  24 in total

1.  The value of PET/CT to assess clinically negative necks.

Authors:  Enver Ozer; Barış Naiboğlu; Ryan Meacham; Cherie Ryoo; Amit Agrawal; David E Schuller
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-15       Impact factor: 2.503

2.  External validation of a prediction model for pathologic N2 among patients with a negative mediastinum by positron emission tomography.

Authors:  Farhood Farjah; Leah M Backhus; Thomas K Varghese; James P Manning; Aaron M Cheng; Michael S Mulligan; Douglas E Wood
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

3.  Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis.

Authors:  Jingbo Wang; Kathy Welch; Luhua Wang; Feng-Ming Spring Kong
Journal:  Clin Lung Cancer       Date:  2011-11-03       Impact factor: 4.785

4.  Is single-station N2 disease on PET-CT an indication for primary surgery in lung cancer patients?

Authors:  Janusz Kowalewski; Tomasz J Szczęsny
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

5.  Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.

Authors:  Do-Hoon Kim; Bong-Il Song; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

6.  Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

7.  Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy.

Authors:  Adil S Akthar; Mark K Ferguson; Matthew Koshy; Wickii T Vigneswaran; Renuka Malik
Journal:  Technol Cancer Res Treat       Date:  2016-06-23

Review 8.  Current role of standardized uptake valuemax-derived ratios in N2 fluorine-18 fluorodeoxyglucose positron-emission tomography non-small cell lung cancer.

Authors:  Duilio Divisi; Mirko Barone; Roberto Crisci
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 9.  Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer.

Authors:  Katsuo Usuda; Aika Funazaki; Ryo Maeda; Atsushi Sekimura; Nozomu Motono; Munetaka Matoba; Hidetaka Uramoto
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-10-04       Impact factor: 1.520

10.  18F-FDG PET-based radiomics model for predicting occult lymph node metastasis in clinical N0 solid lung adenocarcinoma.

Authors:  Lili Wang; Tiancheng Li; Junjie Hong; Mingyue Zhang; Mingli Ouyang; Xiangwu Zheng; Kun Tang
Journal:  Quant Imaging Med Surg       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.